Incyte Corporation

NasdaqGS:INCY Stock Report

Market Cap: US$13.3b

Incyte Management

Management criteria checks 4/4

Incyte's CEO is Herve Hoppenot, appointed in Jan 2014, has a tenure of 10.92 years. total yearly compensation is $16.66M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $26.30M. The average tenure of the management team and the board of directors is 8.9 years and 7.9 years respectively.

Key information

Herve Hoppenot

Chief executive officer

US$16.7m

Total compensation

CEO salary percentage7.8%
CEO tenure10.9yrs
CEO ownership0.2%
Management average tenure8.9yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06
It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

May 03
Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Oct 07

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Sep 29

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

CEO Compensation Analysis

How has Herve Hoppenot's remuneration changed compared to Incyte's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$32m

Jun 30 2024n/an/a

US$97m

Mar 31 2024n/an/a

US$745m

Dec 31 2023US$17mUS$1m

US$598m

Sep 30 2023n/an/a

US$425m

Jun 30 2023n/an/a

US$366m

Mar 31 2023n/an/a

US$324m

Dec 31 2022US$17mUS$1m

US$341m

Sep 30 2022n/an/a

US$876m

Jun 30 2022n/an/a

US$945m

Mar 31 2022n/an/a

US$933m

Dec 31 2021US$14mUS$1m

US$949m

Sep 30 2021n/an/a

US$535m

Jun 30 2021n/an/a

US$338m

Mar 31 2021n/an/a

US$478m

Dec 31 2020US$16mUS$1m

-US$296m

Sep 30 2020n/an/a

-US$335m

Jun 30 2020n/an/a

-US$191m

Mar 31 2020n/an/a

-US$376m

Dec 31 2019US$15mUS$1m

US$447m

Sep 30 2019n/an/a

US$405m

Jun 30 2019n/an/a

US$306m

Mar 31 2019n/an/a

US$253m

Dec 31 2018US$9mUS$996k

US$109m

Sep 30 2018n/an/a

-US$109m

Jun 30 2018n/an/a

-US$102m

Mar 31 2018n/an/a

-US$167m

Dec 31 2017US$16mUS$967k

-US$313m

Compensation vs Market: Herve's total compensation ($USD16.66M) is about average for companies of similar size in the US market ($USD12.85M).

Compensation vs Earnings: Herve's compensation has been consistent with company performance over the past year.

CEO

Herve Hoppenot (64 yo)

10.9yrs

Tenure

US$16,659,526

Compensation

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

Leadership Team

NamePositionTenureCompensationOwnership
Herve Hoppenot
CEO & Chairman10.9yrsUS$16.66m0.20%
$ 26.3m
Pablo Cagnoni
President and Head of Research & Development1.6yrsUS$16.57m0.00087%
$ 115.4k
Christiana Stamoulis
Executive VP & CFO5.8yrsUS$5.08m0.019%
$ 2.5m
Barry Flannelly
Executive VP & GM of North America9.5yrsUS$4.09m0.0062%
$ 822.2k
Steven Stein
Executive VP & Chief Medical Officer9.8yrsUS$5.63m0.0013%
$ 176.4k
Thomas Tray
VP of Finance2.8yrsno data0.0041%
$ 543.7k
Michael Morrissey
Executive VP & Head of Global Technical Operations8.9yrsno data0.019%
$ 2.5m
Ben Strain
Head of Investor Relationsno datano datano data
Sheila Denton
Executive VP1.2yrsno data0.0023%
$ 309.0k
Pamela Murphy
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Paula Swain
Executive Vice President of Human Resources22.3yrsUS$1.31m0.030%
$ 4.0m
Vijay Iyengar
Executive VP of Global Medical Affairsno dataUS$3.30m0.0013%
$ 169.8k

8.9yrs

Average Tenure

60yo

Average Age

Experienced Management: INCY's management team is seasoned and experienced (8.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Herve Hoppenot
CEO & Chairman10.9yrsUS$16.66m0.20%
$ 26.3m
Jean-Jacques Bienaime
Independent Director9.9yrsUS$478.76k0.0080%
$ 1.1m
Julian Baker
Independent Lead Director23.1yrsUS$512.76k0.14%
$ 19.2m
Otis Brawley
Independent Director3.3yrsUS$454.76k0.0031%
$ 405.8k
Jacqualyn Fouse
Independent Director7.9yrsUS$466.26k0.0073%
$ 962.8k
Edmund Harrigan
Independent Director5yrsUS$482.26k0.0072%
$ 957.5k
Katherine High
Independent Director4.8yrsUS$454.76k0.0042%
$ 550.4k
Paul Clancy
Independent Director9.9yrsUS$479.76k0.0086%
$ 1.1m
Susanne Schaffert
Independent Director2.2yrsUS$444.76k0.0015%
$ 198.9k

7.9yrs

Average Tenure

64yo

Average Age

Experienced Board: INCY's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Incyte Corporation is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Thomas RussoBaird
Ishan MajumdarBaptista Research